CTMXCytomX Therapeutics, Inc.
$2.46-26% 1Y
$2.46
$2.4652 weeks$6.75
Latest close: a new 52-week lowOct 8, 2026what changed →
The financials
CytomX Therapeutics, Inc. by the numbers
CytomX Therapeutics, Inc. (CTMX) reported revenue of $1.4M in Q2 2026 (quarter ended Jun 30, 2026), down 92% from the same quarter a year earlier. That came with net loss of $21M. For the full year FY2025, revenue was $76M (−45% year on year) and net income −$17M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.4M | $19M | −92% |
| Operating income | −$24M | −$1.3M | n/a |
| Net income | −$21M | −$154K | n/a |
| Diluted EPS | −$0.09 | $0.00 | n/a |